Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 , an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be … (more)
Source: www.topix.com Via newsmixx: home News